Brooks Boveroux, CFO Photogen Technologies, Inc. The study will evaluate the safety of three different doses of PH-10 in separate patient treatment groups. Patients in the study will each receive a single dose of PH-10 followed by administration of green light on psoriatic plaques. This is the first of several potential applications for PH-10 that we intend to study.
Psoriasis is a chronic, recurrent disease of the skin.
It typically appears as well defined, dry lesions with large silvery scales and marked redness. Its cause is unknown. About 150,000 to 260,000 new cases are diagnosed annually. PH-10 is a photodynamic agent that, when activated, is believed to selectively reduce inflammation of the epidermis and decrease plaque thickness. Photogen develops innovative therapeutic and diagnostic products using proprietary drugs and advanced energy sources.